Viking Therapeutics (VKTX) Enterprise Value (2016 - 2025)
Viking Therapeutics' Enterprise Value history spans 12 years, with the latest figure at -$705.7 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 21.81% year-over-year to -$705.7 million; the TTM value through Dec 2025 reached -$705.7 million, up 21.81%, while the annual FY2025 figure was -$705.7 million, 21.81% up from the prior year.
- Enterprise Value for Q4 2025 was -$705.7 million at Viking Therapeutics, up from -$714.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$135.7 million in Q1 2023 and bottomed at -$963.0 million in Q1 2024.
- The 5-year median for Enterprise Value is -$369.2 million (2023), against an average of -$488.7 million.
- The largest annual shift saw Enterprise Value grew 28.27% in 2022 before it crashed 609.82% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$202.1 million in 2021, then rose by 23.07% to -$155.5 million in 2022, then tumbled by 132.87% to -$362.1 million in 2023, then plummeted by 149.29% to -$902.6 million in 2024, then grew by 21.81% to -$705.7 million in 2025.
- Per Business Quant, the three most recent readings for VKTX's Enterprise Value are -$705.7 million (Q4 2025), -$714.6 million (Q3 2025), and -$807.7 million (Q2 2025).